Bolt Biotherapeutics Q3 2023 Earnings Report

Bolt Biotherapeutics EPS Results

• Actual EPS: -$0.43
• Consensus EPS: -$0.49
• Beat/Miss: Beat by +$0.06
• One Year Ago EPS: N/A

Bolt Biotherapeutics Revenue Results

• Actual Revenue: $2.53 million
• Expected Revenue: $1.60 million
• Beat/Miss: Beat by +$930.00 thousand
• YoY Revenue Growth: N/A

Bolt Biotherapeutics Announcement Details

• Quarter: Q3 2023
• Date: 11/9/2023
• Time: N/A

Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.